Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Ángela Lamarca(Hospital Universitario Fundación Jiménez Díaz), Juan W. Valle(Cancer Research UK Manchester Institute)

The Lancet Oncology

March 30, 2021

10.1016/s1470-2045(21)00027-9

Cited by 741

Related Papers

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

|JAMA|2010|1.4k

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

|The Lancet Oncology|2019|1.2k

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

|NEJM Evidence|2022|1.1k

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1k

Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma

|JAMA|2012|590